GFAP Astrocytopathy Presenting as Rhombo-meningoencephalitis with Initial Negative Antibody Testing
Sina Aghili-Mehrizi1, Kyle Wuthrich1, Priyanka Atit2, Haoming Pang3, Ali Karimi1, Avinash Kolli4, Rebecca Hurst1, Victoria Mazo5, Angelica Rivera Cruz1
1USF Health Neurology, 2University of Miami, 3University of South Florida, Tampa General Hospital, 4Oregon Health & Science University, 5Johns Hopkins All Children's
Objective:
To describe a case of glial fibrillary acidic protein (GFAP) astrocytopathy with an initial presentation of rhombo-meningoencephalitis and negative cerebrospinal fluid (CSF) antibody testing, underscoring the diagnostic value of repeat testing.
Background:
GFAP astrocytopathy is a rare autoimmune syndrome most often presenting as meningoencephalomyelitis with CSF-specific GFAP-IgG. Patients typically develop subacute encephalopathy, longitudinal myelitis, or optic neuritis after a febrile prodrome. Brainstem and cerebellar features are recognized but usually occur alongside encephalopathy or myelitis. MRI may show radial perivascular enhancement, but diagnosis requires CSF antibody detection, as serum testing alone is insufficient.
Design/Methods:
A previously healthy 22-year-old male presented with fever and meningismus after Caribbean travel. Initial brain MRI was normal. One week later, he developed encephalopathy with brainstem and cerebellar dysfunction (vertical gaze palsy, nystagmus, hiccups, dysmetria) and ileus. MRI brain showed a faint right cerebellar T2 hyperintensity. Spine MRI revealed a longitudinally extensive cord lesion from T2–T8. CSF demonstrated lymphocytic pleocytosis and elevated protein. Infectious studies were negative. Autoimmune panel showed a low-titer anti-GQ1b, considered incidental. He received corticosteroids but soon deteriorated with status epilepticus and respiratory failure requiring intubation, after which plasmapheresis was added. Follow-up MRI demonstrated diffuse cortical sulcal T2 changes with leptomeningeal enhancement, and new thalamic, brainstem, and cerebellar lesions; the cord lesion persisted. Repeat CSF testing three weeks after the initial evaluation was positive for GFAP-IgG by IFA, confirmed by cell-based assay. Malignancy screening was negative.
Conclusions:
This case illustrates GFAP astrocytopathy presenting with prominent rhombencephalitic features. It underscores three lessons: (1) GFAP astrocytopathy may mimic isolated brainstem or cerebellar syndromes; (2) early antibody testing may be negative, requiring repeat CSF evaluation; and (3) incidental low-titer antibodies must be interpreted with caution. GFAP astrocytopathy should be considered in patients with fever, encephalopathy, rhombencephalic dysfunction, and myelopathy when infectious studies are negative.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.